If you’ve ever wanted to invest in stocks but have been too overwhelmed, you’re not alone. In fact, you’re probably in the majority, especially during this time of economic volatility. Between Trump’s tariffs, rumored recessions and unpredictable government spending, you may think that learning about the stock market isn’t a good investment for your time. Check Out: Why You Should Start Investing Now (Even If You Only Have $10) For You: 5 Cities You Need To Consider If You're Retiring in 2025 Fortunately, ...

投资评级 - 报告对中国中铁维持"增持"评级 [2] 核心观点 - 公司2025年上半年营收5110.93亿元同比下降5.93% 归母净利润118.27亿元同比下降17.17% [7][8] - 预计2025-2027年归母净利润分别为263.59/279.56/300.40亿元 对应PE为5.3/5.0/4.6倍 [7][8] - 海外新签合同额1248.7亿元同比大幅增长51.6% 境内新签合同额9838.2亿元同比下降1.2% [7][8] 财务表现 - 2024年营业收入11574.39亿元同比下降8.2% 2025年预计收入11173.38亿元同比下降3.5% [6] - 2024年归母净利润278.87亿元同比下降16.7% 2025年预计净利润263.59亿元同比下降5.5% [6] - 上半年销售毛利率8.53%同比下降0.3个百分点 归母净利率2.31%同比下降0.31个百分点 [8] - 经营性现金流净流出796.3亿元 同比多流出102.98亿元 [8] 业务分析 - 基建业务收入4362.46亿元同比下降7.78% 毛利率7.37%同比下降0.53个百分点 [7][8] - 装备制造业务收入137.53亿元同比增长14.39% 毛利率18.16%同比下降0.18个百分点 [7][8] - 境外收入369.71亿元同比增长8.34% 毛利率6.05%同比下降1.28个百分点 [7][8] - 上半年新签合同总额11086.9亿元同比增长2.8% [7][8] 估值指标 - 当前股价5.63元 对应2025年预测PE 5.3倍 PB 0.4倍 [2][6] - 每股净资产12.55元 预计2025-2027年EPS分别为1.07/1.13/1.21元 [2][6] - ROE水平从2024年7.9%预计逐步下降至2027年7.1% [6]

投资评级 - 维持"买入"评级 当前股价对应2025-2027年PE分别为16倍、14倍和12倍 [2][5] 核心观点 - CDMO业务成为业绩增长核心驱动力 2025H1收入同比增长20.32%至12.36亿元 毛利率提升3.95个百分点至44.04% [5] - API中间体与制剂业务阶段性承压但显现企稳迹象 API业务2025H1收入同比下降23.41%至36.03亿元 制剂业务收入同比下降14.2%至5.83亿元 [5] - 公司通过产能扩张和研发投入为长期发展奠定基础 新增多条生产线 CDMO在研项目达803个同比增长44% [5][39] 财务表现 - 2025H1营业收入54.44亿元同比减少15.31% 归母净利润5.63亿元同比减少9.89% [5] - 2025Q2毛利率环比提升3.44个百分点至27.46% 归母净利润环比增长26.54%至3.15亿元 [5] - 预计2025-2027年收入复合增长率约9.6% 归母净利润复合增长率约12.3% [2][5] 业务分项表现 - CDMO业务2025Q2收入6.87亿元同比增长30.11% 毛利率46.93%同比提升4.03个百分点 [5] - API中间体业务2025Q2毛利率环比提升0.37个百分点至13.89% 显示价格见底趋势 [5] - 制剂业务2025Q2毛利率62.01%环比提升1.92个百分点 集采品种价格筑底企稳 [5] 产能与研发进展 - 美国波士顿研发中心建成运营 生物发酵提取中试车间投产 [39] - 新建国际化高端制剂综合车间 新增口服固体制剂等多条生产线 [5][39] - 司美格鲁肽注射液完成III期临床入组 4个ANDA品种申报 [5]

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. I am not a registered investment, tax, or legal advisor or broker and therefore cannot promise or guar ...